| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 3,326 | 4,109 | ||
| Marketable securities | 51,992 | 25,929 | ||
| Prepaid expenses and other assets | 445 | 680 | ||
| Amounts receivable | 260 | 161 | ||
| Deposits | 200 | 200 | ||
| Total current assets | 56,223 | 31,079 | ||
| Deferred offering costs | 456 | - | ||
| Operating lease right-of-use asset, net | 218 | 239 | ||
| Property, plant and equipment, gross | 289 | - | ||
| Less accumulated depreciation | 139 | - | ||
| Property and equipment, net | 150 | 152 | ||
| Deposits | 0 | 0 | ||
| Total non-current assets | 824 | 391 | ||
| Total assets | 57,047 | 31,470 | ||
| Accounts payable | 1,920 | 1,261 | ||
| Accrued liabilities | 3,239 | 2,747 | ||
| Operating lease obligation | 99 | 96 | ||
| Finance lease obligation | 10 | 12 | ||
| Total current liabilities | 5,268 | 4,116 | ||
| Operating lease obligation | 150 | 176 | ||
| Finance lease obligation | 7 | 8 | ||
| Common shares, no par value unlimited authorized 43,072,488 and 42,818,660 shares issued and outstanding, as of june 30, 2025 and december 31, 2024, respectively | - | 0 | ||
| Total non-current liabilities | 157 | 184 | ||
| Paid-in capital | 215,600 | 182,592 | ||
| Accumulated other comprehensive income | 50 | -14 | ||
| Accumulated deficit | -164,028 | -155,408 | ||
| Total shareholders equity | 51,622 | 27,170 | ||
| Total liabilities and shareholders equity | 57,047 | 31,470 | ||
DiaMedica Therapeutics Inc. (DMAC)
DiaMedica Therapeutics Inc. (DMAC)